An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.

ABSTRACT: Adoptive cellular therapy with chimeric antigen receptor (CAR) T cells has emerged as a potential novel treatment for various cancers. In this study, we have generated CAR T cells targeting mucin-1 (MUC1), which is an aberrantly glycosylated antigen overexpressed on breast cancer cells. Two different signaling domains, including CD28 and 41BB, were incorporated and directly compared the superiority of different costimulatory signals. Two different CAR MUC1 constructs were transduced into primary T cells and evaluated their characteristics and antitumor activities against MUC1⁺ cancer cells. CAR MUC1 T cells showed high transduction efficiency and antigen specificity toward MUC1⁺ cancer cell lines and primary breast cancer cells. When coculturing with target cells, the

SUBMITTER: Khuisangeam N 

PROVIDER: S-EPMC9708373 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature